Diabetes Mellitus, Insulin-Dependent

Sanofi Partners with EVOQ Therapeutics to Advance NanoDisc-Based Autoimmune Therapies

1 week ago talkbio0Tagged Autoimmune Diseases, Celiac Disease, Diabetes Mellitus, Insulin-Dependent, EVOQ, Immune Tolerance, License Agreement, Lupus Vulgaris, MOG antibody disease, NanoDisc, Rheumatoid Arthritis, sanofi

Sanofi; EVOQ Therapeutics; NanoDisc; autoimmune disease; license agreement; immune tolerance; celiac disease; type 1 diabetes; MOG antibody disease; rheumatoid arthritis; lupus

Vertex’s Islet Cell Therapy Shows Dramatic Reduction in Dangerous Low Blood Sugar Levels in Type 1 Diabetes Trial

4 months ago talkbio0Tagged Cell Therapy, Diabetes Mellitus, Insulin-Dependent, Endogenous, Hypoglycemia, Insulin, islet, Stem Cell Therapy, zimislecel

Vertex; islet cell therapy; zimislecel; Type 1 diabetes; hypoglycemia; phase 1/2 trial; endogenous insulin; stem cell therapy

FDA Advisory Committee Votes Against Zynquista for Type 1 Diabetes and Chronic Kidney Disease, Despite Support for Subgroup Benefits

12 months ago talkbio0Tagged (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol, Advisory Committees, Chronic Kidney Diseases, Diabetes Mellitus, Insulin-Dependent, Glycemic Control, Inhibitor, lexicon, SGLT1/SGLT2, United States Food and Drug Administration, Zynquista

FDA Advisory Committee, Zynquista (sotagliflozin), Type 1 Diabetes (T1D), Chronic Kidney Disease (CKD), Glycemic Control, SGLT1/SGLT2 Inhibitor, Lexicon Pharmaceuticals